Most retatrutide coverage fixates on one number: 28.3%. But with all four core registrational trials now reporting topline results, the more interesting question has quietly become a dosing question — who actually needs to reach 12mg, and what happens on the way up? Retatrutide dosing is where efficacy, tolerability, supply and eventual price all collide, and it's the part of the story that press releases barely explain.

Here's what is actually new, and what it does and doesn't tell us.

What's new: the fourth core trial closed the set

On 23 July 2026, Eli Lilly announced topline results from two more phase 3 trials in the TRIUMPH programme. In TRIUMPH-2 (adults with type 2 diabetes and obesity or overweight, roughly 1,150 participants), once-weekly retatrutide produced body-weight reductions of up to 20.8% and HbA1c reductions of up to 1.6 percentage points at 80 weeks. In TRIUMPH-3 (adults with obesity and established cardiovascular disease, roughly 1,950 participants), weight reduction reached up to 22.6% at 80 weeks, alongside reported improvements in triglycerides, blood pressure and inflammatory markers.

Two important caveats, stated plainly: these are company topline announcements, not peer-reviewed publications, and the headline figures are "up to" numbers — meaning they reflect the highest dose studied. Full per-dose breakdowns, completer versus treatment-policy analyses and discontinuation detail will only be assessable when the papers and conference presentations land. Until then, nobody outside Lilly can precisely rank the doses.

Lay the four readouts side by side and a pattern emerges:

Trial Population Top-line weight loss (80 weeks)
TRIUMPH-1 Obesity/overweight, no T2D up to ~28.3%
TRIUMPH-2 T2D with obesity/overweight up to ~20.8%
TRIUMPH-3 Obesity + established CVD up to ~22.6%
TRIUMPH-4 Obesity + knee osteoarthritis reported positive

That gradient is not evidence of an inconsistent drug. It's the familiar pattern seen across the whole incretin class: people with type 2 diabetes and people with advanced cardiometabolic disease typically lose less weight than metabolically healthier participants on the same molecule and the same dose. Our clinical trials overview tracks each readout as it moves from press release to publication.

Retatrutide dosing: why the highest dose isn't the default

Every phase 3 headline you read is anchored to the top dose. In practice, dosing in this class works as a titration ladder: start low, step up every few weeks, and stop where benefit and tolerability meet. Semaglutide and tirzepatide both work this way, and plenty of real-world patients settle below the maximum studied dose.

Three reasons the same is likely to be true for retatrutide:

1. Tolerability is dose-linked

Across the TRIUMPH trials the most common adverse events reported were diarrhoea, nausea, constipation and decreased appetite — gastrointestinal effects that, in this drug class, tend to cluster around dose escalation steps. Slower titration is the standard clinical lever. See our safety page for the fuller picture.

2. The target is health, not the biggest number

For someone with type 2 diabetes, a 15% weight loss with a 1.5-point HbA1c drop at a mid dose may be a better clinical outcome than chasing a maximum dose they can't tolerate. TRIUMPH-2's glycaemic data reinforce that weight is only one endpoint that matters.

3. Dose drives cost and supply

Higher doses mean more active drug per pen. That shapes manufacturing capacity — Lilly has committed around US$3.5 billion to a new Lehigh Valley, Pennsylvania injectables site expected to be operational around 2031, explicitly including retatrutide — and it shapes how payers think about tiered pricing. If a meaningful share of patients do well at lower doses, the average cost per patient looks very different from the worst case.

Where regulation actually sits

Retatrutide remains investigational everywhere. Lilly has said it plans to submit a biologics licence application to the FDA in the first quarter of 2027. Separately, on 3 August 2026 the company confirmed an early-access pathway for a narrowly defined group of patients — adults with refractory obesity and serious complications who cannot enrol in a trial — which is compassionate access, not approval, and not a supply channel.

The Australian implication: retatrutide is not TGA-approved, and Lilly's public guidance points to filings from 2027, which places any Australian registration behind the US timeline. Dosing matters locally too — if the effective dose for many people sits below the maximum, that changes the arithmetic for both private pricing and any future PBS submission. Our Australia page covers the local pathway in detail.

What to watch next

  • Full publications and conference presentations for TRIUMPH-2 and TRIUMPH-3, with per-dose efficacy and discontinuation rates.
  • The remaining phase 3 readouts across the wider programme, including sleep apnoea, liver and other cardiometabolic populations.
  • Label language whenever a regulator acts — specifically whether a maintenance dose range is approved rather than a single target dose.

New to the molecule? Start with what is retatrutide, then join the free updates list and we'll email you when a readout is published or a regulator moves.

FAQ

What are the retatrutide doses used in trials?

Phase 3 TRIUMPH trials studied once-weekly injections across multiple dose levels up to 12mg, reached through gradual escalation. Published headline results generally reflect the highest dose, and full per-dose breakdowns are still awaiting peer-reviewed publication.

Do you have to reach 12mg to lose weight on retatrutide?

Not necessarily. In this drug class, lower and mid doses still produce substantial weight loss, and clinicians typically titrate to the dose where benefit and tolerability balance. No final dosing recommendation exists yet because retatrutide is not approved anywhere.

What were the TRIUMPH-2 and TRIUMPH-3 results?

Lilly's July 2026 topline announcements reported up to 20.8% weight loss plus up to 1.6 percentage points of HbA1c reduction in adults with type 2 diabetes (TRIUMPH-2), and up to 22.6% weight loss in adults with obesity and established cardiovascular disease (TRIUMPH-3), both at 80 weeks. These are company press releases, not peer-reviewed papers.

When will retatrutide be approved?

Lilly has said it plans to file a biologics licence application with the FDA in the first quarter of 2027, with other regulators, including the TGA, following on their own timelines. No approval exists in any country today.

Sources

This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA, the FDA or any other regulator. Speak with your GP or a qualified health professional about your own treatment. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.